Programming Grants to Accompany NEH on the Road Exhibitions
Deadline : 9-26-2016
Funding Opportunity : RFA-CA-16-003
CFDA : 93.394|000000
Agency : Department of Health and Human Services
Contact : NIH OER Webmaster
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Eligibility : State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Native American Tribal Governments (Federally recognized)
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Nonprofits Having a 501 (c) (3) Status with the IRS (other than institutions of higher education)
Nonprofits that do not have a 501 (c) (3) status with the IRS (other than institutions of higher education)
Private institutions of higher education
For-profit organizations other than small business
Small businesses
Others
Details :
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of technologies that improve the quality of the samples used for cancer research or clinical care. This includes innovative technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.